Tuesday 13 October 2026
Export AUTL’s income statement to Excel — free account
Autolus Therapeutics PLC Sponsored ADR
AUTL Healthcare Biotechnology
In the quarter to June 2026, revenue grew 118.4%, EPS grew 16.7% and free cash flow grew 67.6%, each against the same quarter a year earlier.
1.65
0.09
−5.17%
Follow AUTL
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
3.63 | 3.97 | 7.03 | 8.48 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(16.99) | (5.62) | (7.87) | (6.39) | |
P/B ratio |
5.69 | 3.37 | 2.97 | 1.63 | |
Price to Tangible BV |
7.56 | 4.09 | 3.35 | 1.77 | |
EV/Sales |
2.56 | 2.19 | 3.90 | 2.24 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.33) | (0.74) | (1.04) | (0.45) | |
EV/FCF |
(1.18) | (0.66) | (0.91) | (0.37) | |
Quick Ratio |
3.60 | 4.07 | 4.44 | 4.83 | |
Current Ratio |
4.89 | 5.80 | 5.94 | 6.19 | |
Net Debt/EBITDA |
3.04 | 4.06 | 3.37 | 5.34 | |
Debt/Assets |
15.76% | 0.00% | 11.34% | 0.00% | |
Debt/Equity |
1.04 | 0.00 | 0.38 | 0.00 | |
Asset Turnover |
0.19 | 0.15 | 0.11 | 0.07 | |
Operating CF/Net income |
0.64 | 0.91 | 0.75 | 0.86 | |
Capex/Depreciation |
(0.34) | (1.00) | 0.34 | (4.92) | |
Interest Coverage |
16.39 | (5.35) | (3.17) | (6.81) | |
Research and Development Expense of Revenue |
61.06% | 80.90% | 146.70% | 131.60% | |
Selling, General and Administrative Expense of Revenue |
90.09% | 152.39% | 147.36% | 171.18% | |
Intangible Assets out of Total Assets |
0.04 | 0.04 | 0.03 | 0.03 | |
Share Based Compensation of Revenue |
10.06% | 13.60% | 14.18% | 18.09% | |
Graham Net Nets |
(0.19) | (0.13) | 0.05 | 0.27 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(66.25%) | (78.99%) | (54.27%) | (50.92%) | |
Free Cash Flow Yield |
(59.62%) | (83.85%) | (61.13%) | (70.72%) | |
Revenue per Share |
0.17 | 0.10 | 0.09 | 0.08 | |
Operating CF per Share |
(0.09) | (0.25) | (0.25) | (0.26) | |
Capex per Share |
0.00 | (0.01) | 0.00 | (0.05) | |
Free Cash Flow per Share |
(0.10) | (0.26) | (0.25) | (0.30) | |
Cash per Share |
0.76 | 0.87 | 1.14 | 1.39 | |
Shareholders Equity per Share |
0.28 | 0.41 | 0.67 | 1.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.28 | 0.41 | 0.67 | 1.00 | |
Free Cash Flow |
(25.98) | (68.00) | (66.44) | (80.40) | |
Working Capital |
267.30 | 305.24 | 362.48 | 431.51 | |
Capital Expenditures |
(0.91) | (2.69) | 0.89 | (12.50) | |
Net Current Asset Value |
(82.30) | (49.40) | 24.98 | 118.08 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.10 | (0.04) | 0.59 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
35.52 | 20.99 | 12.02 | 37.28 | |
Average Payables |
3.39 | 3.16 | 2.53 | 6.19 | |
Average Inventory |
28.69 | 23.94 | 18.67 | — | |
Average Assets |
607.10 | 636.70 | 685.90 | 744.72 | |
Average Common Equity |
210.65 | 239.97 | 302.73 | 371.21 |
Columns are period end dates · fundamentals updated 28 Sep 2026